With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...

Eli Lilly is advancing its diabetes and obesity treatment with an oral drug, orforglipron. In an exclusive interaction, CEO ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

The return on investment in pharma research and development (R&D) has increased from the previous year, with GLP-1 drugs ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...

Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey medications used to treat complex and chronic conditions, according to a new ...

“Ozempic face” refers to the sagging of skin due to rapid weight loss. Experts say it’s preventable by slowing down weight ...

Spending on GLP-1 drugs continues to rise, after outpacing trends among specialty drugs for the first time in 2023, according ...

Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s (NVO) popular ...

GLP-1s are driving traditional drug spending in the U.S. to unprecedented levels, which now outpaces specialty drug spending ...

Equinox's GLP-1 protocol is considered a framework for people taking the drugs, one that addresses workout intensity, ...

Zerodha CEO Nithin Kamath described weight-loss drugs Ozempic and Mounjaro as near 'miracle drugs,' highlighting their ...